CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction

Abstract

Induction treatment incorporating bortezomib diminishes the negative impact of the lack of CD117 expression and aberrancy of CD28 but does not overcome the negative impact of the lack of CD56 expression.